Literature DB >> 27107027

PSD-95 uncoupling from NMDA receptors by Tat- N-dimer ameliorates neuronal depolarization in cortical spreading depression.

Krzysztof Kucharz1, Ida Søndergaard Rasmussen1, Anders Bach2, Kristian Strømgaard2, Martin Lauritzen1,3.   

Abstract

Cortical spreading depression is associated with activation of NMDA receptors, which interact with the postsynaptic density protein 95 (PSD-95) that binds to nitric oxide synthase (nNOS). Here, we tested whether inhibition of the nNOS/PSD-95/NMDA receptor complex formation by anti-ischemic compound, UCCB01-144 (Tat- N-dimer) ameliorates the persistent effects of cortical spreading depression on cortical function. Using in vivo two-photon microscopy in somatosensory cortex in mice, we show that fluorescently labelled Tat- N-dimer readily crosses blood-brain barrier and accumulates in nerve cells during the first hour after i.v. injection. The Tat- N-dimer suppressed stimulation-evoked synaptic activity by 2-20%, while cortical blood flow and cerebral oxygen metabolic (CMRO2) responses were preserved. During cortical spreading depression, the Tat- N-dimer reduced the average amplitude of the negative shift in direct current potential by 33% (4.1 mV). Furthermore, the compound diminished the average depression of spontaneous electrocorticographic activity by 11% during first 40 min of post-cortical spreading depression recovery, but did not mitigate the suppressing effect of cortical spreading depression on cortical blood flow and CMRO2. We suggest that uncoupling of PSD-95 from NMDA receptors reduces overall neuronal excitability and the amplitude of the spreading depolarization wave. These findings may be of interest for understanding the neuroprotective effects of the nNOS/PSD-95 uncoupling in stroke.

Entities:  

Keywords:  Cortical spreading depression; NMDAR; Tat-N-dimer; UCCB01-144; postsynaptic density protein 95; spreading depolarization; stroke

Mesh:

Substances:

Year:  2016        PMID: 27107027      PMCID: PMC5435282          DOI: 10.1177/0271678X16645595

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  25 in total

1.  Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1 and PDZ domain interaction.

Authors:  Y Hayashi; S H Shi; J A Esteban; A Piccini; J C Poncer; R Malinow
Journal:  Science       Date:  2000-03-24       Impact factor: 47.728

2.  Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions.

Authors:  Michelle Aarts; Yitao Liu; Lidong Liu; Shintaro Besshoh; Mark Arundine; James W Gurd; Yu-Tian Wang; Michael W Salter; Michael Tymianski
Journal:  Science       Date:  2002-10-25       Impact factor: 47.728

3.  Development of (17)O NMR approach for fast imaging of cerebral metabolic rate of oxygen in rat brain at high field.

Authors:  Xiao-Hong Zhu; Yi Zhang; Run-Xia Tian; Hao Lei; Nanyin Zhang; Xiaoliang Zhang; Hellmut Merkle; Kamil Ugurbil; Wei Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-19       Impact factor: 11.205

Review 4.  Clinical relevance of cortical spreading depression in neurological disorders: migraine, malignant stroke, subarachnoid and intracranial hemorrhage, and traumatic brain injury.

Authors:  Martin Lauritzen; Jens Peter Dreier; Martin Fabricius; Jed A Hartings; Rudolf Graf; Anthony John Strong
Journal:  J Cereb Blood Flow Metab       Date:  2010-11-03       Impact factor: 6.200

5.  Cerebral metabolic response to low blood flow: possible role of cytochrome oxidase inhibition.

Authors:  Albert Gjedde; Peter Johannsen; Georg E Cold; Leif Ostergaard
Journal:  J Cereb Blood Flow Metab       Date:  2005-09       Impact factor: 6.200

Review 6.  The stroke-migraine depolarization continuum.

Authors:  Jens P Dreier; Clemens Reiffurth
Journal:  Neuron       Date:  2015-05-20       Impact factor: 17.173

7.  A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage.

Authors:  Anders Bach; Bettina H Clausen; Magda Møller; Bente Vestergaard; Celestine N Chi; Adam Round; Pernille L Sørensen; Klaus B Nissen; Jette S Kastrup; Michael Gajhede; Per Jemth; Anders S Kristensen; Patrik Lundström; Kate L Lambertsen; Kristian Strømgaard
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-17       Impact factor: 11.205

8.  Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein.

Authors:  R Sattler; Z Xiong; W Y Lu; M Hafner; J F MacDonald; M Tymianski
Journal:  Science       Date:  1999-06-11       Impact factor: 47.728

9.  Stargazin regulates synaptic targeting of AMPA receptors by two distinct mechanisms.

Authors:  L Chen; D M Chetkovich; R S Petralia; N T Sweeney; Y Kawasaki; R J Wenthold; D S Bredt; R A Nicoll
Journal:  Nature       Date:  2000 Dec 21-28       Impact factor: 49.962

Review 10.  The role of spreading depression, spreading depolarization and spreading ischemia in neurological disease.

Authors:  Jens P Dreier
Journal:  Nat Med       Date:  2011-04-07       Impact factor: 53.440

View more
  11 in total

Review 1.  'Spreading depression of Leão' and its emerging relevance to acute brain injury in humans.

Authors:  Martin Lauritzen; Anthony J Strong
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

2.  The impact of dihydropyridine derivatives on the cerebral blood flow response to somatosensory stimulation and spreading depolarization.

Authors:  Írisz Szabó; Orsolya M Tóth; Zsolt Török; Dániel Péter Varga; Ákos Menyhárt; Rita Frank; Dóra Hantosi; Ákos Hunya; Ferenc Bari; Ibolya Horváth; László Vigh; Eszter Farkas
Journal:  Br J Pharmacol       Date:  2019-04-01       Impact factor: 8.739

3.  Effects of Dimeric PSD-95 Inhibition on Excitotoxic Cell Death and Outcome After Controlled Cortical Impact in Rats.

Authors:  Jens Bak Sommer; Anders Bach; Hana Malá; Mikko Gynther; Ann-Sofie Bjerre; Marie Gajhede Gram; Linda Marschner; Kristian Strømgaard; Jesper Mogensen; Darryl S Pickering
Journal:  Neurochem Res       Date:  2017-08-21       Impact factor: 3.996

4.  Administration of a novel high affinity PICK1 PDZ domain inhibitor attenuates cocaine seeking in rats.

Authors:  Christopher Turner; Marta De Luca; Jordan Wolfheimer; Nicole Hernandez; Kenneth Lindegaard Madsen; Heath D Schmidt
Journal:  Neuropharmacology       Date:  2019-12-02       Impact factor: 5.250

5.  Shedding Light on the Blood-Brain Barrier Transport with Two-Photon Microscopy In Vivo.

Authors:  Krzysztof Kucharz; Nikolay Kutuzov; Oleg Zhukov; Mette Mathiesen Janiurek; Martin Lauritzen
Journal:  Pharm Res       Date:  2022-05-16       Impact factor: 4.200

6.  Drug Delivery Strategies to Overcome the Blood-Brain Barrier (BBB).

Authors:  Hans Christian Cederberg Helms; Mie Kristensen; Lasse Saaby; Gert Fricker; Birger Brodin
Journal:  Handb Exp Pharmacol       Date:  2022

7.  PSD-95 protects the pancreas against pathological damage through p38 MAPK signaling pathway in acute pancreatitis.

Authors:  Yinan Guo; Weikai Hu; Xueyan Wang; Chunyun Li; Tianyu Cui; Ruixia Liu; Junqi He; Chenghong Yin
Journal:  Exp Biol Med (Maywood)       Date:  2021-04-01

8.  Preso regulates NMDA receptor-mediated excitotoxicity via modulating nitric oxide and calcium responses after traumatic brain injury.

Authors:  Peng Luo; Xin Li; Xiuquan Wu; Shuhui Dai; Yuefan Yang; Haoxiang Xu; Da Jing; Wei Rao; Hongyu Xu; Xiangyu Gao; Zhou Fei; Hongbing Lu
Journal:  Cell Death Dis       Date:  2019-06-24       Impact factor: 8.469

9.  Apolipoprotein M-bound sphingosine-1-phosphate regulates blood-brain barrier paracellular permeability and transcytosis.

Authors:  Krzysztof Kucharz; Martin Lauritzen; Mette Mathiesen Janiurek; Rana Soylu-Kucharz; Christina Christoffersen
Journal:  Elife       Date:  2019-11-25       Impact factor: 8.140

10.  Cationic Arginine-Rich Peptides (CARPs): A Novel Class of Neuroprotective Agents With a Multimodal Mechanism of Action.

Authors:  Bruno P Meloni; Frank L Mastaglia; Neville W Knuckey
Journal:  Front Neurol       Date:  2020-02-25       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.